Findings
The COVID-19 pandemic has highlighted the need for decentralized clinical trials (DCTs) due to the closure of traditional trial sites.
There is a lack of a national electronic medical system, which poses a challenge for digital risk minimization.
The current regulatory framework is not fully equipped to handle the rapid advancements in digital health technologies.

Recommendations
Increase the adoption and integration of decentralized clinical trials (DCTs) to ensure continuity of research during disruptions.
Develop a national electronic medical system to support digital health initiatives and improve data integration.
Enhance collaboration between regulatory bodies and technology developers to create flexible and adaptive regulatory frameworks.
Encourage the use of real-world data and digital endpoints in clinical trials to improve efficiency and relevance.
Promote patient engagement and input in the development and implementation of digital health technologies.

Regulatory Considerations
The need for standardization and integration of digital health technologies across different platforms and systems.
The importance of developing regulatory guidelines that can adapt to the rapid pace of technological advancements.
The necessity for collaboration between regulatory bodies and standards development organizations to ensure effective oversight of digital health technologies.